European shares close at record high as healthcare outperforms; US shutdown in focus

European equities, including the STOXX 600 and FTSE 100, closed at record highs, primarily driven by a 5.4% surge in healthcare stocks following a U.S.-Pfizer deal that alleviated sector uncertainty regarding drug pricing. This positive momentum occurred despite the commencement of a U.S. government shutdown, which is expected to increase market volatility and complicate the Federal Reserve's economic assessment and potential interest rate decisions due to likely delays in key data releases, such as the September employment report, even as disappointing private payrolls data raised bets on an October rate cut.

Analysis

European equity markets, including the STOXX 600 and FTSE 100, reached record highs, driven overwhelmingly by a significant re-rating in the healthcare sector. The pan-European STOXX 600 advanced 1.2%, while the healthcare sub-index surged 5.4%, its largest single-day gain since November 2008. This rally was catalyzed by a U.S.-Pfizer agreement to lower drug prices for Medicaid, which provided substantial regulatory clarity and reduced uncertainty for the pharmaceutical industry, leading to double-digit percentage gains for stocks like AstraZeneca (+11.2%) and Merck (+10%). This positive momentum occurred despite a deteriorating macroeconomic backdrop, including the start of a U.S. government shutdown which is expected to delay key economic data and complicate the Federal Reserve's policy decisions. Concurrently, fresh data revealed a contraction in euro zone manufacturing activity and accelerating inflation, signaling underlying economic weakness in the region. The market's divergence was highlighted by a 13% drop in Tate & Lyle following a profit warning and a 0.4% dip in the travel and leisure sector, indicating the rally's narrow focus.

Key Decisions for Investors

• The Pfizer deal has materially de-risked the European pharmaceutical sector from a U.S. regulatory standpoint, suggesting investors should re-evaluate their exposure to names that saw significant gains like AstraZeneca and Merck, assessing whether the new clarity justifies a sustained higher valuation.
• Investors must prepare for increased market volatility due to the U.S. government shutdown, as the potential delay of key employment data impairs the Federal Reserve's visibility and could lead to unpredictable policy moves.
• Despite the headline index highs in Europe, the underlying weak manufacturing data and accelerating inflation from the region warrant a cautious stance on cyclically-exposed sectors, favoring industries with non-cyclical drivers like healthcare.
• The stark underperformance of individual names like Tate & Lyle underscores the importance of focusing on company-specific fundamentals rather than relying on broad market momentum, which is currently concentrated in a single sector.